GLP-1-derived therapies and risk of sarcopenia: myth or reality?

GLP-1-based therapies may lead to a clinically significant reduction in body weight while raising concerns about excessive skeletal muscle mass loss.

• Some studies report excessive loss of skeletal muscle mass (SMM) with GLP-1-based therapies, while others suggest potential protective effects against sarcopenia through improved muscle quality.
• Mixed findings regarding muscle strength, function, and structure indicate a lack of consensus on the impact of GLP-1 therapies on skeletal muscle.
• Misinterpretation of body composition changes may contribute to the controversy surrounding the effects of GLP-1 therapies on muscle health.
• There is a need for further studies, particularly in older patients who may be at higher risk for sarcopenia.
• Despite concerns, the overall benefit/risk ratio of GLP-1 therapies appears positive for most patients with type 2 diabetes and/or obesity.

AI simplified